AAIC 2021 – Prothena – Alzheimer’s Vaccine Data and Next-Gen Alzheimer’s Treatment Data

Hideki Garren, MD, PhD, Chief Medical Officer at Prothena discusses data from two presentations at the Alzheimer’s Association International Conference (AAIC); PRX012, Prothena’s next generation anti-amyloid beta (Aβ) antibody and the dual Aβ-tau vaccine being developed for the prevention and treatment of Alzheimer’s Disease (AD).   He talks about the company’s approach to addressing the AD global healthcare crisis.  

H​ideki Garren, M.D., Ph.D.​, Chief Medical Officer​. Dr. Garren has served as our Chief Medical Officer since April 2021. Before joining Prothena, between 2013 and 2021 Dr. Garren was with F. Hoffmann-La Roche Ltd. (Roche) & Genentech Inc. and most recently served as Vice President, Global Head of Neuroimmunology with responsibility for leading Roche’s Neuroimmunology franchise team. Prior to Roche, between 2011 and 2013, Dr. Garren held the role of Executive Director, Translational Medicine Expert in Neuroscience with Novartis Pharma. Dr. Garren also served as Co-Founder, Executive Vice President, Chief Scientific Officer, and Chief Operating Officer of Bayhill Therapeutics, Inc., a company he started in 2002 based on a technology platform he co-invented while at Stanford University. He currently serves on the board of directors of Coya Therapeutics, a privately-held clinical-stage biotechnology company. Dr. Garren earned his Bachelor of Science from the California Institute of Technology and his MD and PhD from the University of California, Los Angeles (UCLA). He completed his internship in internal medicine at UCLA, and his residency in neurology and fellowship in neuroimmunology at Stanford University.